The US Market for Rx to OTC Switches, 2015 Edition - Analysis of the $7.8 Billion Industry
DUBLIN, Feb. 23, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/rn97w3/the_us_market_for) has announced the addition of the "The US Market for Rx to OTC Switches, 7th Edition" report to their offering.
Over the past 38 years the U.S. Rx-to-OTC market has grown into a $7.8 billion market
This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products, once only available by prescription.
The current climate of patient-consumer awareness of health issues is continuing to influence the Rx-to-OTC market. Consumers are more prepared to take responsibility for their own health and are willing to purchase medicines over the counter. An increased focus on cost-savings, coupled with the effects of advertising and promotion, result a higher rate of OTC purchases. Aging baby boomers, many of which are taking greater interest in their health, have created a growing Rx-to-OTC industry in America. It is anticipated that Rx-to-OTC switch products will continue to grow as interest from both consumers and developers continue to expand.
The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments in which Rx-to-OTC switches are available. These include:
- Allergy, Cough, Cold, and Sinus Products
- Analgesics, NSAIDs, and Pain Treatments
- Anti-Infectives
- Gastrointestinal Drugs
- Hair Loss Products
- Hormones
- Oral Care
- Overactive Bladder
- Rectal Ointments
- Sleep-aids
- Smoking Cessation
- Weight Loss
In addition to the areas with switches in place, this report has identified other areas which may be open to Rx-to-OTC switches in the future.
These include:
- Blood Products
- BPH Treatments
- Cholesterol-reducing Drugs
- Hormone Replacement Therapies
- Migraine Treatments
- Opioid Overdose Treatment
- Osteoporosis Treatments
- Sexual Dysfunction/ Erectile Dysfunction
Key Topics Covered:
- Executive Summary
- The Otc Drug Industry
- Allergy, Cough, Cold, And Sinus Products
- Analgesics And Other Pain Relievers
- Anti-Infectives
- Gastrointestinal Drugs
- Smoking Cessation Products
- Other Drug Classifications
- Profiles For Major Rx-To-Otc Participants
- Company Directory
- List Of Exhibits
- Executive Summary
Companies Featured:
- Bayer
- Boehringer Ingelheim
- GlaxoSmithKline
- Johnson & Johnson
- Novartis
- Perrigo Company
- Pfizer
- Prestige Brands
- Procter & Gamble
- Reckitt Benckiser
- Sanofi/Chattem
- TEVA
For more information visit http://www.researchandmarkets.com/research/rn97w3/the_us_market_for
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article